[go: up one dir, main page]

PE20141597A1 - Triazolopiridinas sustituidas - Google Patents

Triazolopiridinas sustituidas

Info

Publication number
PE20141597A1
PE20141597A1 PE2014000944A PE2014000944A PE20141597A1 PE 20141597 A1 PE20141597 A1 PE 20141597A1 PE 2014000944 A PE2014000944 A PE 2014000944A PE 2014000944 A PE2014000944 A PE 2014000944A PE 20141597 A1 PE20141597 A1 PE 20141597A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
compounds
triazolopyridines
substitute
Prior art date
Application number
PE2014000944A
Other languages
English (en)
Inventor
Volker Schulze
Dirk Kosemund
Antje Margret Wengner
Gerhard Siemeister
Detlef Stockigt
Michael Bruening
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of PE20141597A1 publication Critical patent/PE20141597A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cosmetics (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

SE REFIERE A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES a); R2 ES b); R6 ES c) EL CUAL ESTA OPCIONALMENTE SUSTITUIDO CON HALOGENO O METILO; R9 ES C1-C3-ALQUILO, HIDROXI-C1-C3-ALQUILO, ENTRE OTROS; R5a ES C1-C4-ALCOXI, HALO-C1-C4-ALCOXI, C1-C4-ALQUILO; R5b ES R7-S(=O)2-, ENTRE OTROS; R7 ES C1-C3-ALQUILO O CICLOPROPILO; Q ES CH O N; * INDICA EL PUNTO DE UNION DEL GRUPO CON EL RESTO DE LA MOLECULA; R3 ES H; R4 ES H; R5 ES H O C1-C3-ALQUILO. SON COMPUESTOS PREFERIDOS: (2R)-N-[4-(2-{[2-ETOXI-4-(METILSULFONIL)FENIL]AMINO}[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL)FENIL]-2-(4-FLUOROFENIL)PROPANAMIDA; (2R)-2-(4-FLUOROFENIL)-N-[4-(2-{[2-METOXI-4-(METILSULFONIL)FENIL]AMINO}-[1,2,4]TRIAZOLO[1,5-a]PIRIDIN-6-IL)FENIL]PROPANAMIDA; ENTRE OTROS. SE REFIERE TAMBIEN A UN METODO DE PREPARACION DE DICHOS COMPUESTOS, A UNA COMPOSICION Y A UNA COMBINACION FARMACEUTICA
PE2014000944A 2011-12-12 2012-12-10 Triazolopiridinas sustituidas PE20141597A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11193011 2011-12-12

Publications (1)

Publication Number Publication Date
PE20141597A1 true PE20141597A1 (es) 2014-11-07

Family

ID=47427291

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014000944A PE20141597A1 (es) 2011-12-12 2012-12-10 Triazolopiridinas sustituidas

Country Status (39)

Country Link
US (1) US9663510B2 (es)
EP (1) EP2791136B1 (es)
JP (1) JP6181664B2 (es)
KR (1) KR20140105552A (es)
CN (1) CN104114552B (es)
AP (1) AP4017A (es)
AR (1) AR089143A1 (es)
AU (1) AU2012350751B2 (es)
BR (1) BR112014014184A2 (es)
CA (1) CA2858683A1 (es)
CL (1) CL2014001546A1 (es)
CO (1) CO6980657A2 (es)
CR (1) CR20140275A (es)
CU (1) CU20140068A7 (es)
CY (1) CY1116958T1 (es)
DK (1) DK2791136T3 (es)
DO (1) DOP2014000133A (es)
EC (1) ECSP14004812A (es)
ES (1) ES2550677T3 (es)
GT (1) GT201400111A (es)
HR (1) HRP20151103T1 (es)
HU (1) HUE025937T2 (es)
IL (1) IL232930A (es)
JO (1) JO3111B1 (es)
MA (1) MA35826B1 (es)
MX (1) MX2014007057A (es)
PE (1) PE20141597A1 (es)
PH (1) PH12014501319A1 (es)
PL (1) PL2791136T3 (es)
PT (1) PT2791136E (es)
RS (1) RS54288B1 (es)
RU (1) RU2632464C1 (es)
SG (1) SG11201402820SA (es)
SI (1) SI2791136T1 (es)
TN (1) TN2014000254A1 (es)
UA (1) UA112096C2 (es)
UY (1) UY34515A (es)
WO (1) WO2013087579A1 (es)
ZA (1) ZA201404031B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872506A1 (en) * 2012-07-10 2015-05-20 Bayer Pharma Aktiengesellschaft Method for preparing substituted triazolopyridines
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
AR096469A1 (es) * 2013-06-06 2015-12-30 Bayer Pharma AG Composiciones farmacéuticas que comprenden compuestos del tipo triazolpiridinas
EA201600003A1 (ru) * 2013-06-11 2016-06-30 Байер Фарма Акциенгезельшафт КОМБИНАЦИИ ДЛЯ ЛЕЧЕНИЯ РАКА, СОДЕРЖАЩИЕ ИНГИБИТОР Mps-1 КИНАЗЫ И ИНГИБИТОР МИТОЗА
PT3008062T (pt) * 2013-06-11 2017-06-07 Bayer Pharma AG Derivados de profármaco de triazolopiridinas substituídas
EP2860177A3 (en) 2013-09-20 2015-06-10 Bayer Intellectual Property GmbH Synthesis of functionalized arenes
KR102330668B1 (ko) * 2014-05-19 2021-11-24 유디씨 아일랜드 리미티드 고효율의 형광 유기 발광 소자
MA41136A (fr) * 2014-12-09 2017-10-17 Bayer Pharma AG Composés pour le traitement d'un cancer
CA2970565A1 (en) 2014-12-15 2016-06-23 Bayer Pharma Aktiengesellschaft Antibody-drug conjugates (adcs) of ksp inhibitors with aglycosylated anti-tweakr antibodies
CN105985241A (zh) * 2015-01-27 2016-10-05 邵阳学院 α-取代苯乙酸酯类化合物α-糖苷酶抑制作用及其应用
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
JP2018525334A (ja) 2015-06-23 2018-09-06 バイエル ファーマ アクチエンゲゼルシャフト キネシンスピンドルタンパク質(ksp)阻害剤の抗tweakr抗体との抗体薬物複合体
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
TW201800408A (zh) 2016-06-15 2018-01-01 拜耳製藥公司 Mps-1抑制劑
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
US10968216B2 (en) 2016-10-27 2021-04-06 Bayer Aktiengesellschaft 4,5-annulated 1,2,4-triazolones
WO2018114804A1 (de) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Spezifische antikörper-wirkstoff-konjugate (adcs) mit ksp-inhibitoren
MX2019007641A (es) 2016-12-21 2019-09-09 Bayer Pharma AG Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente.
CN106831555B (zh) * 2017-01-22 2019-09-24 中国农业大学 吡啶酰胺类化合物及其制备方法与应用
KR102668688B1 (ko) 2018-07-23 2024-05-24 삼성디스플레이 주식회사 유기 발광 소자
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
KR102661468B1 (ko) 2019-02-15 2024-04-30 삼성디스플레이 주식회사 유기 발광 소자 및 이를 포함한 전자 장치
US20210151691A1 (en) 2019-11-14 2021-05-20 Samsung Display Co., Ltd. Organic light-emitting device and apparatus including the same
AU2023228543A1 (en) * 2022-03-04 2024-08-22 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US6693116B2 (en) * 2001-10-08 2004-02-17 Hoffmann-La Roche Inc. Adenosine receptor ligands
AU2004275694B2 (en) 2003-06-30 2008-03-06 Bizbiotech Co., Ltd. Compounds, compositions and methods
WO2007065010A2 (en) 2005-12-02 2007-06-07 Hif Bio, Inc. Anti-angiogenesis compounds
CA2662074A1 (en) 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
AR067562A1 (es) 2007-07-18 2009-10-14 Novartis Ag Compuestos heterociclicos inhibidores de kinasa
WO2009024824A1 (en) 2007-08-23 2009-02-26 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
AU2008291075A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
EA201000797A1 (ru) 2007-11-27 2011-02-28 Целльзом Лимитид Аминотриазолы в качестве ингибиторов pi3k
WO2010092015A1 (en) 2009-02-10 2010-08-19 Cellzome Limited Urea triazololo [1, 5-a] pyridine derivatives as pi3k inhibitors
JP2012517971A (ja) 2009-02-13 2012-08-09 フォーヴィア・ファーマシューティカルズ キナーゼ阻害薬としての[1,2,4]トリアゾロ[1,5−a]ピリジン類
CA2760077A1 (en) 2009-04-29 2010-11-04 Marcus Koppitz Substituted imidazoquinoxalines
CN102596932A (zh) 2009-09-04 2012-07-18 拜耳医药股份有限公司 作为酪氨酸苏氨酸激酶抑制剂的取代氨基喹喔啉
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
MX2012008260A (es) 2010-01-15 2012-08-17 Janssen Pharmaceuticals Inc Novedosos derivados de triazol sustituidos como moduladores de la gamma secretasa.
US20110190269A1 (en) 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
JP2011246389A (ja) * 2010-05-26 2011-12-08 Oncotherapy Science Ltd Ttk阻害作用を有する縮環ピラゾール誘導体
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
CN103608350B (zh) * 2011-04-21 2015-11-25 拜耳知识产权有限责任公司 三唑并吡啶类化合物

Also Published As

Publication number Publication date
EP2791136B1 (en) 2015-07-29
RU2632464C1 (ru) 2017-10-05
SG11201402820SA (en) 2014-06-27
RS54288B1 (sr) 2016-02-29
AR089143A1 (es) 2014-07-30
TN2014000254A1 (en) 2015-09-30
PT2791136E (pt) 2015-11-04
MA35826B1 (fr) 2014-12-01
AU2012350751A1 (en) 2014-06-26
AP2014007731A0 (en) 2014-06-30
US20150210683A1 (en) 2015-07-30
HRP20151103T1 (xx) 2015-11-20
DOP2014000133A (es) 2014-07-31
US9663510B2 (en) 2017-05-30
UY34515A (es) 2013-07-31
KR20140105552A (ko) 2014-09-01
JP2015500308A (ja) 2015-01-05
HK1203200A1 (en) 2015-10-23
PH12014501319A1 (en) 2014-09-08
WO2013087579A1 (en) 2013-06-20
CO6980657A2 (es) 2014-06-27
ZA201404031B (en) 2016-09-28
IL232930A0 (en) 2014-08-03
CY1116958T1 (el) 2017-04-05
NZ625815A (en) 2016-07-29
CR20140275A (es) 2014-08-13
ECSP14004812A (es) 2015-11-30
MX2014007057A (es) 2014-08-08
CL2014001546A1 (es) 2014-10-24
DK2791136T3 (en) 2015-10-26
JP6181664B2 (ja) 2017-08-16
SI2791136T1 (sl) 2015-11-30
UA112096C2 (uk) 2016-07-25
CA2858683A1 (en) 2013-06-20
CN104114552B (zh) 2016-12-28
GT201400111A (es) 2015-11-30
BR112014014184A2 (pt) 2017-06-13
AU2012350751B2 (en) 2017-07-06
HUE025937T2 (en) 2016-05-30
AP4017A (en) 2017-01-28
CN104114552A (zh) 2014-10-22
CU20140068A7 (es) 2014-12-26
EP2791136A1 (en) 2014-10-22
IL232930A (en) 2016-07-31
PL2791136T3 (pl) 2015-12-31
JO3111B1 (ar) 2017-09-20
ES2550677T3 (es) 2015-11-11

Similar Documents

Publication Publication Date Title
PE20141597A1 (es) Triazolopiridinas sustituidas
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
PE20141582A1 (es) Pirimidinas anilladas sustituidas y uso de las mismas
CL2015002635A1 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
PE20131343A1 (es) Derivados de acido benzoico
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
PE20190710A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201000775A1 (ru) Ингибиторы бета-лактамазы
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA201591908A1 (ru) Конденсированные гетероциклические соединения в качестве ингибиторов протеинкиназы
EA201290255A1 (ru) Способы и композиции для лечения рака
EA201390682A1 (ru) Спирооксиндольные антагонисты mdm2
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
EA201391719A1 (ru) Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний
MX383688B (es) Derivados de piridona amida como agonistas de canales de sodio nav1. 8 y el uso de los mismos en el tratamiento de dolor.
EA201190017A1 (ru) Аминоэфирные производные алкалоидов и их медицинские композиции
CY1124329T1 (el) N-(6-((2r,3s)-3,4-δiyδpoξyboytan-2-yλoξy)-2-(4-φθοροβενζυλοθειο)πυριμιδιν-4-υλ)-3-μεθυλαζετιδιν-1-σουλφοναμιδιο ως ρυθμιστης του υποδοχεα χημειοκινων
MX381913B (es) Composiciones y metodos para el tratamiento de la mielofibrosis.
PE20141593A1 (es) Imidazopiridazinas sustituidas con amino
MA32622B1 (fr) Derives de carbonate de quinuclidine et composition medicinale les comprenant
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina

Legal Events

Date Code Title Description
FC Refusal